Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 366-373

  Cella, David ^a   Zagari, Martin J ^a   Vandoros, Christina ^a   Gagnon, Dennis D ^a   Hurtz, Hans Jürgen ^a   Nortier, Johan W R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; HEMOGLOBIN;

ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HUMAN; INTERNET; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; ADOLESCENT; BLOOD TRANSFUSION; COMPARATIVE STUDY; FATIGUE; METABOLISM; MULTICENTER STUDY; NEOPLASM; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA; BLOOD TRANSFUSION; DOUBLE-BLIND METHOD; EPOETIN ALFA; FATIGUE; HEALTH STATUS INDICATORS; HEMATINICS; HEMOGLOBINS; HUMANS; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 0037440036     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.136     Document Type: Article

References (24)

1. Vogelzang NJ, Breitbart W, Cella D, et al: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripartite assessment survey. Semin Hematol 34:4-12, 1997
2. Curt GA, Breitbart W, Cella D, et al: Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5:353-360, 2000
3. Barrett-Lee PJ, Bailey NP, O'Brien ME, et al: Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82:93-97, 2000
4. Coiffier B, Guastalla J-P, Pujade-Lauraine E, et al: Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: Results of a retrospective survey. Eur J Cancer 37:1617-1623, 2001
5. Cella D: Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 25:43-46, 1998 (suppl 7)
6. Abels RI: Recombinant human erythropoietin in the treatment of the anemia of cancer. Acta Haematol 87:S4-S11, 1992 (suppl 1)
7. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21:21-28, 1994 (suppl 3)
8. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
9. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998
10. Dammacco F, Castoldi G, Rödjer S, for the Multiple Myeloma Study Group: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172-179, 2001
11. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
12. Littlewood TJ, Bajetta E, Nortier JWR, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
13. Cella D: The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13-19, 1997 (suppl 2)
14. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms of cancer with the functional assessment of cancer therapy (FACT) measurement system. J Pain Sympt Manage 13:63-74, 1997
15. Kazis LE, Andersen JJ, Meenan RF: Effect sizes for interpreting changes in health studies. Med Care 27:5178-5189, 1989
16. Nunnally JC, Bernstein IR: Psychometric Theory (ed 3). New York, NY, McGraw-Hill, 1994
17. Cohen J: Statistical Power Analysis for the Behavioral Sciences (ed 2). Hillsdale, NJ, Lawrence Erlbaum Associates, 1998
18. Kraemer HC: Reporting the size of effects in research studies to facilitate assessment of practical or clinical significance. Psychoneuroendocrinology 17:527-536, 1992
19. Guyatt GH, Osoba D, Wu AW, et al: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371-383, 2002
20. Shakespeare A: Quality of life in cancer. Int J Pharm Med 14:66-67, 2000
21. Samsa G, Edelman D, Rothman ML, et al: Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15:141-155, 1999
22. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
23. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? J Clin Epidemiol 55:285-295, 2002
24. Cella D: Assessment methods for quality of life in cancer patients: The FACIT measurement system. Int J Pharm Med 14:78-81, 2000